Search by Medical Condition

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Clinical Trials for Amyloidosis

• EPIC-ATTR: A Study to Evaluate the Effect of Eplontersen on the Transthyretin Reduction and Long-term Safety in Chinese Subjects With Transthyretin Amyloid Cardiomyopathy
• Optimize First-line Treatment for AL Amyloidosis With t (11; 14)
• Study of ALXN2220 Versus Placebo in Adults With ATTR-CM
• A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Immunoglobulin Light Chain (AL) Amyloidosis Receiving ABBV-383 as an Intravenous (IV) Infusion
• MAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)
• Efficacy and Safety of Intravenous YOLT-201 for Transthyretin Amyloidosis Cardiomyopathy
• FKC288 for Relapsed or Refractory Systemic Light Chain (AL) Amyloidosis
• A Study of AT-02 in Subjects With Systemic Amyloidosis.
• A Study to Investigate Safety and Efficacy With SAR445514 in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) and Relapsed/Refractory Light-chain Amyloidosis (RRLCA)
• Selinexor and Lenalidomide for Consolidation and Maintenance Treatment in Multiple Myeloma Post-transplant
• Administration of the SGLT-2 Inhibitor Dapagliflozin in the Patients With Amyloid Cardiomyopathy
• Probiotic Supplementation Reduces Gastrointestinal Symptoms During the Therapy and Improves Therapeutic Response in AL Amyloidosis
• Study of AMDX-2011P in Subjects With CAA
• Antibiotics Against Amyloid Angiopathy
• An Extension Study to Assess Long-Term Safety of Eplontersen in Adults With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)
• A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ALN-TTRSC04 in Healthy Subjects
• Evuzamitide as SPECT/CT Imaging Agent for Diagnosis of Transthyretin Amyloidosis
• The Effect of Trimetazidine on Mitochondrial Function, Myocardial Performance, and Invasive Hemodynamics in Patients Diagnosed With Wild-Type Transthyretin Cardiac Amyloidosis
• Molecular Imaging of Myocardial Fibrosis in Cardiac Amyloidosis
• Study of AT-02 in Healthy Volunteers and Subjects With Systemic Amyloidosis
• Safety, Efficacy, and Pharmacokinetics of Tafamidis in Patients With Transthyretin-mediated Amyloidosis Post Orthotopic Heart Transplantation
• Venetoclax, Daratumumab, and Dexamethasone for Systemic Light-Chain Amyloidosis With Translocation (11;14) (ALTITUDE)
• Venetoclax-Dexamethasone in Relapsed and/or Refractory t(11;14) Amyloidosis
• A Research Study to Look at How a New Medicine Called NNC6019-0001 Works and How Safe it is for People Who Have Heart Disease Due to Transthyretin (TTR) Amyloidosis
• A Study of Daratumumab-Based Therapies in Participants With Amyloid Light Chain (AL) Amyloidosis
• A Study to Evaluate Organ Level Uptake Repeatability of 124I AT-01 in Subjects With Systemic Amyloidosis
• SGLT2 Inhibitors in ATTR
• A Study to Characterize the Biodistribution of 124I-Labeled AT-03 in Patients With Systemic Amyloidosis
• Phase 1/2 Study of ZN-d5 for the Treatment of Relapsed or Refractory Light Chain (AL) Amyloidosis
• Efficacy of [18F]Florbetaben PET for Diagnosis of Cardiac AL Amyloidosis
• Phase I/IIa Study of Belantamab Mafodotin in Relapsed or Refractory AL Amyloidosis
• A Study to Assess the Long-Term Safety and Efficacy of ION-682884 in Patients With Hereditary Transthyretin-Mediated Amyloid Polyneuropathy
• Isatuximab Plus Pomalidomide and Dexamethasone Association for Patients With AL Amyloidosis Not in VGPR or Better After Any Previous Therapy
• COVID-19 VAX Booster Dosing in Patients With Hematologic Malignancies
• Spectrum of Peripheral and Autonomic Neuropathies in Patients With wtATTR Amyloidosis and Response to Patisiran Therapy"
• Pilot Deprescribing Trials for Beta-blockers in Cardiac Amyloidosis
• Open-Label Safety Study of Acoramidis (AG10) in Symptomatic ATTR Participants
• Selinexor for Treatment of Light Chain Amyloidosis With Relapsed/Refractory Disease
• A Study to Evaluate the Efficacy and Safety of Birtamimab in Mayo Stage IV Patients With AL Amyloidosis
• The Effect of Tafamidis on Transthyretin Stabilization, Safety, Tolerability and Efficacy in Transthyretin Amyloid Polyneuropathy Patients
• Isatuximab and Bendamustine in Systemic Light Chain Amyloidosis
• Clinical Study of ATTR-CM
• Prevalence of Transthyretin Cardiac Amyloidosis in Clinically Significant Aortic Stenosis
• Daratumumab and Pomalidomide in Previously Treated Patients With AL Amyloidosis
• Efficacy and Safety of Acoramidis (AG10) in Subjects With Transthyretin Amyloid Polyneurophathy (ATTRibute-PN)
• Venetoclax, MLN9708 (Ixazomib Citrate) and Dexamethasone for the Treatment of Relapsed or Refractory Light Chain Amyloidosis
• ION-682884 in Patients With TTR Amyloid Cardiomyopathy
• The Effect Of Tafamidis Meglumine In Transthyretin Amyloid Polyneuropathy Patients
• A Study to Assess the Safety and Efficacy Of Tafamidis In Chinese Participants With Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
• A Single Dose Study to Evaluate the Pharmacokinetics of Acoramidis Modified Release Formulations in Healthy Subjects
• Isatuximab as Upfront Therapy for the Treatment of High Risk AL Amyloidosis
• A Phase 3 Study of ALXN2060 in Japanese Participants With Symptomatic ATTR-CM
• A Study of Belantamab Mafodotin in Patients With Relapsed or Refractory AL Amyloidosis
• Comparison of BTD and BCD Based Regimens in the Treatment of AL Amyloidosis
• MRI-visible Enlarged Perivascular Spaces and the Alteration of Lymphatic Drainage System in CAA
• A Study to Evaluate the Effectiveness and Safety of CAEL-101 in Patients With Mayo Stage IIIa AL Amyloidosis
• A Study to Evaluate the Effectiveness and Safety of CAEL-101 in Patients With Mayo Stage IIIb AL Amyloidosis
• Daratumumab Combined With Bortezomib and Dexamethasone in Mayo 04 Stage III Light Chain Amyloidosis
• AHEAD 3-45 Study: A Study to Evaluate Efficacy and Safety of Treatment With Lecanemab in Participants With Preclinical Alzheimer's Disease and Elevated Amyloid and Also in Participants With Early Preclinical Alzheimer's Disease and Intermediate Amyl
• Efficacy and Safety of AG10 in Subjects With Transthyretin Amyloid Polyneurophathy
• Novel Imaging Tools in Newly-diagnosed Patients With Cardiac AL Amyloidosis
• First-in-Human Study of NI006 in Patients With Amyloid Transthyretin Cardiomyopathy
• A Study to Evaluate the Safety and Tolerability of CAEL-101 in Patients With AL Amyloidosis
• Frontline Lenalidomide for AL Amyloidosis Involving Myocardium
• Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Relapsed/Refractory Light Chain Amyloidosis Patients Previously Exposed to Daratumumab
• Modeling the Relationships Between Functional Connectivity and Amyloid Deposition in Alzheimer's Disease
• HELIOS-B: A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy
• NEURO-TTRansform: A Study to Evaluate the Efficacy and Safety of Eplontersen (Formerly Known as ION-682884, IONIS-TTR-LRx and AKCEA-TTR-LRx) in Participants With Hereditary Transthyretin-Mediated Amyloid Polyneuropathy
• CARDIO-TTRansform: A Study to Evaluate the Efficacy and Safety of AKCEA-TTR-LRx in Participants With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)
• A Study of Daratumumab Monotherapy in Previously Untreated Patients With Stage 3B Light Chain (AL) Amyloidosis
• A Clinical Study of Melphalan Flufenamide (Melflufen) and Dexamethasone for Patients With Immunoglobulin Light Chain (AL) Amyloidosis
• Molecular Imaging of the Underlying Mechanism of Cardiotoxicity in Patients With Light Chain Amyloidosis Using PET/CT
• MCLENA-1: A Clinical Trial for the Assessment of Lenalidomide in Amnestic MCI Patients
• APOLLO-B: A Study to Evaluate Patisiran in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR Amyloidosis With Cardiomyopathy)
• Multimodal Biomarkers for Diagnosis and Prognosis in CAA
• A Study to Desensitize Allergic Reactions to Treatments for Blood Disorders
• Multiple Ascending Dose Study in Healthy Subjects
• Patisiran in Patients With Hereditary Transthyretin-mediated Amyloidosis (hATTR Amyloidosis) Disease Progression Post-Liver Transplant
• Efficacy and Safety of AG10 in Subjects With Transthyretin Amyloid Cardiomyopathy
• Detection of Amyloidosis in Multiple Myeloma Patients by [18F]Florbetaben Positron Emission Tomography
• HELIOS-A: A Study of Vutrisiran (ALN-TTRSC02) in Patients With Hereditary Transthyretin Amyloidosis (hATTR Amyloidosis)
• A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AKCEA-TTR-LRx in Healthy Volunteers and Patients With Hereditary Transthyretin-Mediated Amyloidosis
• Alzheimer's PET Imaging in Racially/Ethnically Diverse Adults
• 24 Month Open Label Study of the Tolerability and Efficacy of Inotersen in TTR Amyloid Cardiomyopathy Patients
• 124I-p5+14 Injection Safety in Subjects With Systemic Amyloidosis
• Ixazomib Maintenance Study in Patients With AL Amyloidosis
• Assessment of 18F-Florbetaben Whole-body PET for the Detection of Cardiac and Extracardiac Sites of Amyloid Deposits
• A Study of NPT189 in Healthy Subjects
• Short-term Effects of TOLCAPONE on Transthyretin Stability in Subjects With Leptomeningeal TTR Amyloidosis (ATTR)
• Pro-arrhythmic Potential of GSK3039294 in Healthy Subjects
• Application of Amyloid PET in Cerebral Amyloid Angiopathy
• A Study of Doxycycline and Tauroursodeoxycholic Acid (Doxy/TUDCA) Plus Standard Supportive Therapy Versus Standard Supportive Therapy Alone in Cardiac Amyloidosis Caused by Transthyretin
• A Trial of Doxycycline vs. Standard Supportive Therapy in Newly-diagnosed Cardiac AL Amyloidosis Patients Undergoing Bortezomib-based Therapy
• Biodistribution of 89Zirconium-labelled GSK2398852 Using PET Imaging
• Transthyretin Cardiac Amyloidosis in HFpEF
• BCD With or Without Doxycycline in Mayo Stage II-III Light Chain Amyloidosis Patients
• Daratumumab After Stem Cell Transplant in Treating Patients With Multiple Myeloma
• A Study of PRX004 in Subjects With Amyloid Transthyretin (ATTR) Amyloidosis
• Cardiac Uptake of 18F Florbetapir in Patients Undergoing Chemotherapy
• Siltuximab to Decrease Symptom Burden After Autologous Stem Cell Transplantation for Patients With Multiple Myeloma and AL Amyloidosis
• Copper 64Cu-DOTA-Daratumumab Positron Emission Tomography in Diagnosing Patients With Relapsed Multiple Myeloma
• Daratumumab, Ixazomib, and Dexamethasone in AL Amyloidosis
• Lenalidomide, Dexamethasone, and Elotuzumab With or Without Cyclophosphamide in Treating Patients With Relapsed Primary Amyloidosis
• Ixazomib In Combination With Cyclophosphamide And Dexamethasone for Newly Diagnosed AL Amyloidosis
• Assessment of Cardiac Fixation During PET Using a New Drug Within Amyloid Cardiac Injuries.
• A Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared to CyBorD Alone in Newly Diagnosed Systemic Amyloid Light-chain (AL) Amyloidosis
• Renal AL Amyloid Involvement and NEOD001
• Study in Subjects With Light Chain (AL) Amyloidosis
• Ibrutinib With or Without Bortezomib and Dexamethasone in Treating Patients With Relapsed or Refractory Immunoglobulin Light Chain Amyloidosis
• PET/MRI Evaluation of Cardiac Amyloid
• Sleep Quality and Amyloid-Beta Kinetics
• Multiple Treatment Session Study to Assess GSK2398852 Administered Following and Along With GSK2315698
• The Role of F-18 Florbetapir in the Early Detection of Cardiac Amyloidosis
• Trial of Venetoclax (ABT-199) and Dexamethasone for Relapsed or Refractory Systemic AL Amyloidosis
• Propylene Glycol-Free Melphalan Hydrochloride (Evomela) in AL Amyloidosis Patients
• Thalidomide/Dexamethasone Treatment And PET Evaluation In Organ Involvemenet of Cardiac Amyloidosis
• Phase 1 Study of GSK2315698 in Healthy Japanese Subjects
• Expanded Access Protocol of Patisiran for Patients With Hereditary ATTR Amyloidosis (hATTR)
• Ixazomib Rollover Study
• Study of Captisol Enabled Melphalan and Pharmacokinetics for Patients With Multiple Myeloma or Light Chain Amyloidosis That Are Receiving an Autologous Transplant.
• Daratumumab for the Treatment of Patients With AL Amyloidosis
• Daratumumab Therapy for Patients With Refractory or Relapsed AL Amyloidosis
• A Safety and Tolerability Study of an Investigational Drug, ALN-TTRSC02, in Healthy Subjects
• Vinorelbine and Gemcitabine in Myeloma
• Long-term Safety of Tafamidis in Subjects With Transthyretin Cardiomyopathy
• Ilaris (Canakinumab) in Patient With Periodic Fever, Aphthous Stomatitis, Pharyngitis and Cervical Adenitis (PFAPA)
• The PRONTO Study, a Global Phase 2b Study of NEOD001 in Previously Treated Subjects With Light Chain (AL) Amyloidosis
• The Effect of an Antisense Oligonucleotide to Lower Transthyretin (TTR) Levels on the Progression of -Wild-type TTR Involving the Heart
• Open-label Extension Study of NEOD001 in Subjects With Light Chain (AL) Amyloidosis
• A Safety Study of GSK3039294 in Healthy Volunteers and Patients With Systemic Amyloidosis
• The Study of an Investigational Drug, Revusiran (ALN-TTRSC), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis in Patients Whose Disease Has Continued to Worsen Following Liver Transplant
• Idelalisib for Immunoglobulin M (IgM)-Associated Primary (AL) Amyloidosis
• A Dose Escalation Study of Carfilzomib Taken With Thalidomide and Dexamethasone in Relapsed AL Amyloidosis
• The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis in Patients Who Have Already Been Treated With ALN-TTR02 (Patisiran)
• Trial of High Dose Melphalan/Stem Cell Transplant With or Without Bortezomib
• Bortezomib for Immunoglobulin Light Chain(AL) Amyloidosis
• Depletion of Serum Amyloid P Component to Enhance the Immune Response to DNA Vaccination
• A Study of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis or Hereditary Periodic Fevers Who Participated in the CACZ885G2301E1, CACZ885G2306 or CACZ885N2301 Studies
• ENDEAVOUR: Phase 3 Multicenter Study of Revusiran (ALN-TTRSC) in Patients With Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC)
• The VITAL Amyloidosis Study, a Global Phase 3, Efficacy and Safety Study of NEOD001 in Patients With AL Amyloidosis
• A Extension Study to Evaluate Revusiran (ALN-TTRSC) in Patients With Transthyretin (TTR) Cardiac Amyloidosis
• A Study To Evaluate The Difference In iPad-Based Cognitive Video Game (Akili Interactive's Project: EVO) Performance In Amyloid-Positive Versus Amyloid-Negative Healthy Elderly Volunteers
• Study of Chimeric Fibril-Reactive Monoclonal Antibody 11-1F4 in Patients With AL Amyloidosis
• Doxycycline to Upgrade Organ Response in Light Chain (AL) Amyloidosis Trial
• Study of SOM0226 in Familial Amyloid Polyneuropathy
• Open-Label Extension Assessing Long Term Safety and Efficacy of IONIS-TTR Rx in Familial Amyloid Polyneuropathy (FAP)
• Escitalopram Effects on CSF Amyloid Beta
• Combined Bone Marrow and Renal Transplantation for Hematologic Disorders With End Stage Renal Disease
• Vyndaqel Drug Use Investigation (Regulatory Post Marketing Commitment Plan)
• Modulation of CSF Amyloid-beta Concentrations Via Behavioral Sleep Deprivation and Pharmacological Sleep Induction
• Study of Efficacy and Safety of Canakinumab in Patients With Hereditary Periodic Fevers
• A Study of the Safety, Tolerability and Pharmacokinetics of ALN-TTR02 in Japanese Healthy Volunteers
• Safety and Efficacy Study of Doxycycline/UrsoDeoxyCholicAcid on Disease Progression in ATTR Amyloidosis
• A Trial for the Treatment of Cardiac AL-Amyloidosis With the Green Tea Compound Epigallocatechin-3-gallate (TAME-AL)
• Bortezomib and Dexamethasone Followed by ASCT Compared With ASCT Alone in Treating Patients With AL Amyloidosis
• Safety and Efficacy of Tafamidis in Patients With Transthyretin Cardiomyopathy
• Phase 2 Study to Evaluate ALN-TTRSC (Revusiran) in Patients With Transthyretin (TTR) Cardiac Amyloidosis
• Depression in the Elderly and Cerebral Amyloid Plaques: Characterization by [18F] AV-45 Affectives Symptoms and Amyloïd Plaques (ASAP)
• The Study of ALN-TTR02 (Patisiran) for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis in Patients Who Have Already Been Treated With ALN-TTR02 (Patisiran)
• APOLLO: The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis
• Ixazomib Citrate, Cyclophosphamide, and Dexamethasone in Treating Patients With Previously Untreated Symptomatic Multiple Myeloma or Light Chain Amyloidosis
• Doxycycline and TUDCA in Patients With Transthyretin Amyloid Cardiomyopathy
• Autologous Stem Cell Transplant Followed By Maintenance Therapy in Treating Elderly Patients With Multiple Myeloma
• A Phase 1, Single- and Multi-Dose, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered ALN-TTRSC (Revusiran) in Healthy Volunteers
• Pomalidomide With Melphalan and Dexamethasone for Untreated Systemic AL Amyloidosis
• A Safety Study of Carfilzomib in Patients With Previously-Treated Systemic Light Chain Amyloidosis
• A Study to Evaluate the Safety of GSK2398852 When Co-administered With GSK2315698 in Patients With Systemic Amyloidosis
• Efficacy and Safety of Inotersen in Familial Amyloid Polyneuropathy
• First-line Pomalidomide, Bortezomib, and Dexamethasone For AL Amyloidosis or LCDD
• Phase 1/2, Open Label, Dose Escalation Study of NEOD001 in Subjects With Light Chain (AL) Amyloidosis
• Imaging Cardiac Amyloidosis: A Pilot Study Using F-18 Florbetapir Positron Emission Tomography
• Safety and Effect of Doxycycline in Patients With Amyloidosis
• Study of Dexamethasone Plus IXAZOMIB (MLN9708) or Physicians Choice of Treatment in Relapsed or Refractory Systemic Light Chain (AL) Amyloidosis
• Safety and Tolerability of Patisiran (ALN-TTR02) in Transthyretin (TTR) Amyloidosis
• A Phase I/II Trial of Pomalidomide and Dexamethasone in Subjects With Previously-Treated AL Amyloidosis
• Trial to Evaluate Safety, Tolerability, and Parmacokinetics of ALN-TTR02 in Healthy Volunteer Subjects
• High Cut-off Hemodialysis in Patients With Advanced Cardiac AL Amyloidosis and End Stage Renal Disease
• Risk-adapted Therapy for Primary Systemic (AL) Amyloidosis
• Epigallocatechingallate (EGCG) in Cardiac AL Amyloidosis
• Pomalidomide and Dexamethasone (PDex) in AL Amyloidosis
• The Effect Of Tafamidis For The Transthyretin Amyloid Polyneuropathy Patients With V30M Or Non-V30M Transthyretin
• The Effect of Diflunisal on Familial Transthyretin Amyloidosis
• SAP Depleter Dose Assessment Study in Patients
• Bortezomib/Dexamethasone (BD), Followed By Autologous Stem Cell Transplantation and Maintenance Bortezomib/Dexamethasone For the Initial Treatment of Monoclonal Immunoglobulin Deposition Disease (MIDD) Associated With Multiple Myeloma and AL Amyloid
• SAP Depleter Dose Escalation Study in Healthy Volunteers
• Study of Oral Ixazomib in Adult Participants With Relapsed or Refractory Light Chain Amyloidosis
• A Trial for Systemic Light-chain (AL) Amyloidosis
• Study of Bortezomib +HSCT in Primary Systemic Amyloidosis (AL)
• Positron Emission Tomography (PET) Amyloid Imaging of the Brain in Healthy Young Adult Subjects
• Bendamustine and Dexamethasone in Patients With Relapsed AL Amyloidosis
• Efficacy and Safety Study of KIACTA in Preventing Renal Function Decline in AA Amyloidosis
• Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant
• Lendexal in Patients With Primary Systemic Amyloidosis (AL) Newly Diagnosed
• Safety, Efficacy and Pharmacokinetics of Doxycycline Plus Tauroursodeoxycholic Acid in Transthyretin Amyloidosis
• Positron Emission Tomography (PET) Imaging of Brain Amyloid Compared to Post-Mortem Levels
• Trial to Evaluate Safety and Tolerability of ALN-TTR01 in Transthyretin (TTR) Amyloidosis
• Florbetaben (BAY94-9172) PET (Positron Emission Tomography) Imaging in MCI (Mild Cognitive Impairment) Patients
• Bortezomib and Dexamethasone Followed by High-Dose Melphalan and Stem Cell Transplantation for Primary (AL) Amyloidosis
• Melphalan and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Systemic Light-Chain Amyloidosis
• Bortezomib, Cyclophosphamide, and Dexamethasone in Treating Patients With Primary Systemic Light Chain Amyloidosis
• Lenalidomide, Dexamethasone and Cyclophosphamide in Amyloidosis (AL)
• Immune Mobilization of Autologous Peripheral Blood Stem Cells Using Interleukin-2 and GM-CSF
• Phase II Study of Florbetaben (BAY94-9172) PET Imaging for Detection/Exclusion of Cerebral β-amyloid.
• Safety And Efficacy Evaluation Of Fx-1006A In Subjects With Transthyretin Amyloidosis
• Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy
• A Pilot Study of Lenalidomide, Melphalan and Dexamethasone in AL Amyloidosis
• A Trial of Treatment With Lenalidomide-Melphalan-Dexamethasone in Patients With Primary (AL) Amyloidosis
• Florbetapir F 18 PET Imaging of Beta-amyloid in Parkinson's Disease Patients
• Phase III Study of the Correlation Between Florbetapir F18 PET Imaging and Amyloid Pathology in the Brain
• An Extension of Study Fx-005 Evaluating Long-Term Safety And Clinical Outcomes Of Fx-1006A In Patients With Transthyretin Amyloid Polyneuropathy
• Melphalan, Bortezomib, and Stem Cell Transplant in Treating Patients With Primary Systemic Amyloidosis
• Phase II Study of Florbetaben (BAY 94-9172) PET Imaging for Detection/Exclusion of Cerebral β-amyloid in Patients With Probable Alzheimer's Disease Compared to Healthy Volunteers
• The Effects Of Fx-1006A On Transthyretin Stabilization And Clinical Outcome Measures In Patients With V122I Or Wild-Type TTR Amyloid Cardiomyopathy
• Melphalan, Lenalidomide, and Dexamethasone in Treating Patients With Primary Systemic Amyloidosis
• Trial of Two Stem Cell Doses To Reduce Transplant Induced Symptom Burden
• The Effects of Fx-1006A on Transthyretin Stabilization and Clinical Outcome Measures in Patients With Non-V30M Transthyretin Amyloidosis
• Lenalidomide in Combination With Melphalan and Dexamethasone in Newly-diagnosed Light-chain (AL)-Amyloidosis
• Cyclophosphamide, Lenalidomide and Dexamethasone (CLD) for Previously Treated Patients With AL Amyloidosis
• Lenalidomide, Cyclophosphamide, and Dexamethasone in Treating Patients With Primary Systemic Amyloidosis
• CC-4047 and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma or Amyloidosis
• High-Dose Chemotherapy With or Without Total-Body Irradiation Followed by Autologous Stem Cell Transplant in Treating Patients With Hematologic Cancer or Solid Tumors
• Bortezomib, Melphalan, and Dexamethasone in Treating Patients With Primary Amyloidosis or Light Chain Deposition Disease
• Low-Dose Melphalan and Dexamethasone Compared With High-Dose Melphalan Followed By Autologous Stem Cell Transplant in Treating Patients With Primary Systemic Amyloidosis
• Melphalan and Autologous Stem Cell Transplant Followed By Bortezomib and Dexamethasone in Treating Patients With Previously Untreated Systemic Amyloidosis
• Safety and Efficacy Study of Fx-1006A in Patients With Familial Amyloidosis
• Intensive Versus Conventional Treatment in Patients With Primary Amyloidosis
• Open-Label Phase 1/2 Study of VELCADE for Injection in Patients With Light-chain (AL)-Amyloidosis
• The Effect of Diflunisal on Familial Amyloidosis
• Phase II Trial of Enbrel in Patients With Primary Systemic Amyloidosis
• Efficacy of CC-5013 (Revlimid or Lenalidomide) in Patients With Primary Systemic Amyloidosis
• Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without Cancer
• CC-5013 With or Without Dexamethasone in Treating Patients With Primary Systemic Amyloidosis
• Melphalan, Thalidomide, and Dexamethasone in Treating Patients With Newly Diagnosed, Previously Untreated Primary Systemic Amyloidosis
• Tandem Autologous Stem Cell Transplantation in Treating Patients With Primary Systemic (AL) Amyloidosis
• 2nd Autologous Stem Cell Transplant in Patients With Persistent/Recurrent (AL) Amyloidosis
• S0115, High-Dose Melphalan and Autologous Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma or Primary Systemic Amyloidosis
• Amifostine and Melphalan in Treating Patients With Primary Systemic Amyloidosis Who Are Undergoing Peripheral Stem Cell Transplantation
• Study of the Safety and Efficacy of NC-503 in Secondary (AA) Amyloidosis
• Iododoxorubicin in Treating Patients With Primary Systemic Amyloidosis
• Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver Dysfunction
• Study of High-Dose Melphalan and Autologous Stem Cell Transplantation in Patients With Primary Light Chain Amyloidosis
• Fludarabine Phosphate and Total-Body Radiation Followed by Donor Peripheral Blood Stem Cell Transplant and Immunosuppression in Treating Patients With Hematologic Malignancies
• Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without Cancer
• Chemotherapy Plus Peripheral Stem Cell Transplant in Treating Patients Who Have Multiple Myeloma or Primary Systemic Amyloidosis
• Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine, Mycophenolate Mofetil, Donor Lymphocyte Infusion in Treating Patients With Hematopoietic Cancer
• 4'-Iodo-4'-Deoxydoxorubicin in Treating Patients With Primary Systemic Amyloidosis
• High-Dose Melphalan Plus Peripheral Stem Cell Transplantation in Treating Patients With Primary Systemic Amyloidosis
• S9628 Dexamethasone Plus Interferon Alfa in Treating Patients With Primary Systemic Amyloidosis
• High-Dose Melphalan Followed by Peripheral Stem Cell Transplant in Treating Patients With Amyloidosis